Evidence map›Paper›PMID 37779152›Full record

ReviewMedical oncology (Northwood, London, England)2023

Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.

Sara Abdalrazzaq M Noraldeen, Irodakhon Rasulova, Repudi Lalitha, Farah Hussin, Hashem O Alsaab, Ahmed Hussien Alawadi, Ali Alsaalamy, Nidhal Hassan Sayyid, Adnan Taan Alkhafaji, Yasser Fakri Mustafa and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 5 countries.

Sara Abdalrazzaq M NoraldeenDepartment of Oncology and Metabolism, University of Tabuk, Tabuk, Saudi Arabia.
Irodakhon RasulovaSchool of Humanities, Natural & Social Sciences, New Uzbekistan University, 54 Mustaqillik Ave., 100007, Tashkent, Uzbekistan.
Repudi LalithaDepartment of Pharmaceutical Analysis, Chaitanya Deemed to be University, Hyderabad, Telangana, India. repudilalitha@gmail.com.
Farah HussinMedical Technical College, Al-Farahidi University, Baghdad, Iraq.
Hashem O AlsaabDepartment of Pharmaceutics and Pharmaceutical Technology, Taif University, 21944, Taif, Saudi Arabia.
Ahmed Hussien AlawadiCollege of Technical Engineering, The Islamic University, Najaf, Iraq.
Ali AlsaalamyCollege of Technical Engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna, 66002, Iraq.
Nidhal Hassan SayyidCollege of Nursing, National University of Science and Technology, Dhi Qar, Iraq.
Adnan Taan AlkhafajiCardiology Department, College of Medicine, Al-Ayen University, Thi-Qar, Iraq.
Yasser Fakri MustafaDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq.
Sepideh Karkon ShayanStudent Research Committee, School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran. sepidehshayan76@gmail.com.ORCID http://orcid.org/0000-0002-1278-723X
Thi Qar University · IQAl-Farahidi UniversityChaitanya Bharathi Institute of Technology · INGonabad University of Medical Sciences · IRImam Ja’afar Al-Sadiq UniversityNew Uzbekistan University · UZTaif University · SAUniversity of Babylon · IQUniversity of Mosul · IQUniversity of Tabuk · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment with chimeric antigen receptor (CAR) T cells indicated remarkable clinical responses with liquid cancers such as hematological malignancies; however, their therapeutic efficacy faced with many challenges in solid tumors due to severe toxicities, antigen evasion, restricted and limited tumor tissue trafficking and infiltration, and, more importantly, immunosuppressive tumor microenvironment (TME) factors that impair the CAR T-cell function adds support survival of cancer stem cells (CSCs), responsible for tumor recurrence and resistance to current cancer therapies. Therefore, in-depth identification of TME and development of more potent CAR platform targeting CSCs may overcome the raised challenges, as presented in this review. We also discuss recent stemness-based innovations in CAR T-cell production and engineering to improve their efficacy in vivo, and finally, we propose solutions and strategies such as oncolytic virus-based therapy and combination therapy to revive the function of CAR T-cell therapy, especially in TME of solid tumors in future.

Indexed as

NeoplasmsReceptors, Chimeric AntigenHumansImmunotherapyImmunotherapy, AdoptiveNeoplasm Recurrence, LocalT-LymphocytesTumor MicroenvironmentReceptors, Chimeric AntigenAdoptive cell therapyCancer stem celliPSCOncolytic virusStemnessTumor microenvironment

Identifiers

PMID37779152
OpenAlexW4387231725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.